27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group | 6th – 9th October 2022 | Kochi, India
27th Annual Meeting of Asia-Pacific Blood and Marrow Transplantation Group
October 06, 2022 (Thrusday) – Day 1 |
|||
1.30 PM – 6.00 PM |
Opening Remarks |
||
7:00 PM onwards |
Industry Sponsored Dinner Symposium |
October 07, 2022 (Friday) – Day 2 |
|||
09:00 AM – 09:15 AM |
Opening Remarks |
||
09:20 AM – 11:20 AM |
Session 1 |
Presidential Symposium – Joint Session of ASTCT/EBMT/APBMT/WBMT |
|
09:20 AM – 09:50 AM |
Activity and Regulation of Cellular Therapies in North America |
||
09:50 AM – 10:20 AM |
Activity and Regulation of Cellular Therapies in Europetreatment |
||
10:20 AM -10:50 AM |
Activity and Regulation of Cellular Therapies in Asia Pacific Region |
||
10:50 AM – 11:20 AM |
Global Trends in Cellular Therapy and its integration with HSCT- WBMT Perspective |
||
11:20 AM -12:00 PM |
Plenary Session |
Clinical Aspects of TIM-3 in myeloid malignacies – Its relevance in cellular therapy |
|
12:00 PM- 1:00 PM |
Industry Sponsored Dinner Symposium |
||
01:00 PM – 03:00 PM |
Session 2 & 3 |
Acute Leukemia |
Pediatric Session |
01:00 PM – 01:30 PM |
AML-CR1 Allo-HSCT in the era of genomics |
Haplo-idential transplant in Thalassemia Major |
|
01:30 PM – 02:00 PM |
Prophylactic/Pre-emptive Strategies in AML post allo transplant. What's relevant in 2022? |
HSCT in Primary HLH |
|
02:00 PM – 02:30 PM |
ALL-CR1 Allo-HSCT in 2022: Who should get it? |
Gene Therapy or HSCT in Storage Disorders |
|
02:30 PM – 03:00 PM |
Bridge to HSCT for relapsed ALL |
Upfront Haplo transplant for Aplastic anemias – Are we justified ? |
|
03:00 PM- 03:30 PM |
BREAK |
||
03:30 PM- 05:30 PM |
Session 4 & 5 |
Lymphoma/Myeloma |
Pediatric Sessions |
03:30 PM- 04:00 PM |
Managing Post transplant relapses for Multiple Myeloma Chandramouli Nagarajan, Singapore |
ALL – Optimising conditioning for children |
|
04:00 PM- 04:30 PM |
Checkpoint Inhibitors or allogeneic transplant in refractory HD Young Rok Do, Daegu |
Cellular Therapy in metastatic neuroblastoma |
|
04:30 PM- 05:00 PM |
Optimising choices of salvage therapies in DLBCL |
Late effects post transplant in children and its management Revathi Raj, Chennai |
|
05:00 PM- 05:30 PM |
Auto or allo transplant in PTCL |
Transplantation in Sicle cell Disease- when and how? |
|
05:30 PM- 07:00 PM |
Poster Session |
||
7:00 PM onwards |
Industry Sponsored Dinner Symposium |
October 8 2022 (Saturday) – Day 3 |
|||
08:00 AM-09:30 AM |
APBMT Business Meeting |
||
09:30 AM- 10:10 AM |
Plenary Session |
Cellular therapy Beyond B Cell Malignacies- He Huang , Hangzhou |
|
10:10 AM- 12:10 PM |
Session 6 & 7 |
Immunology of Transplantation / GVHD |
Infections |
10:10 AM- 10:40 AM |
Non-CNI based GVHD-Prophylaxis strategy: Options and Current Clinical use |
Does Gut Microbiome predict infections post transplant |
|
10:40 AM- 11:10 AM |
Novel insights in biology and treatment of acute GVHD |
Treatment of MDR Gram negative infections- molecular basis of treatment |
|
11:10 AM- 11:40 AM |
Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: |
PTLD- risk factors, preventive strategies and treatment |
|
11:40 AM- 12:10 PM |
Novel insights in biology and treatment of chronic GVHD |
Newer insights in treatment of CMV infections |
|
12:10PM- 1:10 PM |
Industry Sponsored Lunch Symposium |
||
01:10 PM-03:10 PM |
Session 8 & 9 |
Oral Presentations |
Oral Presentations |
03:10 PM- 03:30 PM |
BREAK |
||
03:30 PM- 04:30 PM |
General Assembly Meeting |
||
04:30 PM -06:30 PM |
Session 10 & 11 |
Cellular Therapies Beyond Transplantation |
Post Transplant complications |
04:30 PM -05:00 PM |
Cellular Therapy for post transplant infections |
Management of non-infective pulmonary complications:- what is new? |
|
05:00 PM -05:30 PM |
Indigenous CAR-T product for B Cell Malignancies |
Diagnosis and mangement of poor graft function |
|
05:30 PM -06:00 PM |
Gene Corrected HSCT- a reality |
Novel conditioning regimens to decrease regimen related toxicities |
|
06:00 PM -06:30 PM |
Various DLI strategies post transplant to prevent and treat relapse in hematological malignancies |
TA-TMA- diagnosis, risk factors and treatment |
|
7.00 PM Onwards |
Industry Sponsored Dinner Symposium |
October 9, 2022 (Sunday) – Day 4 |
|||
09:00 AM -09:40 AM |
Plenary Session |
Role of Cell-free DNA profiling in hematopoietic cell transplantation Iwijn De Vlaminck, New York |
|
09:45 AM – 11:45 PM |
Session 12 &13 |
Alternate Donor Transplantation |
Oral Presentations |
09:45 AM – 10:15 PM |
How to select donor for T replete and T deplete haplo transplants |
||
10:15 AM – 10:45 PM |
Bone marrow or PBSC- does it really matter in T replete haplo transplants |
||
10:45 AM – 11:15 PM |
Haplo vs MUD vs Cord in acute leukemia- current status |
||
11:15 AM – 11:45 PM |
Is it the end of the road for cord transplant? |
||
11:45 AM – 12:45 PM |
Industry Sponsored Lunch Symposium |
||
12:45 PM- 01:00 PM |
Award Announcements and Closing Remarks |
Raghu Rajagopal
Executive Advisor, ISBMT
exad@isbmt.org
Ambili Arun Kumar
Chief Operating Officer, ISBMT
coo@isbmt.org
Maheshwari G
Program Manager, ISBMT
pm@isbmt.org
Copyright ©2022 Annual Meeting 2022. All rights reserved.
Powered by WordPress & Designed by Elisyan India Pvt. Ltd.